SCHEMBL3250585

SCHEMBL3250585

COc1ccc2[nH]c3c(C)c4ccnc(NCCCCCCNc5c6cc7c([nH]c8ccc(OC)cc87)c(C)c6cc[n+]5C)c4cc3c2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 4/20 0.67
ACHE P22303 4/20 0.47
BCHE P06276 3/20 0.47
RECQL P46063 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 6/20 0.41
RAB9A P51151 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
POLB P06746 3/20 0.41
MAPT P10636 3/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
TLR3 O15455 1/20 0.41
NR3C1 P04150 1/20 0.41
PKM P14618 1/20 0.41
NPC1 O15118 3/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
ALDH1A1 P00352 6/20 0.39
HPGD P15428 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL2313371 1.00 KIT (0.67) KITACHEBCHERECQLTDP1
Iodide SCHEMBL5363520 0.87 KIT (0.64) KITACHEBCHERECQLTDP1
SCHEMBL2315040 0.85 KIT (0.73) KITACHEBCHERECQLKDM4E
SCHEMBL2312023 0.85 KIT (0.73) KITACHEBCHERECQLKDM4E
SCHEMBL2314192 0.83 KIT (0.76) KITACHEBCHERECQLKDM4E
SCHEMBL2311284 0.82 KIT (0.76) KITACHEBCHERECQLKDM4E
SCHEMBL6027031 0.81 KIT (0.60) KITACHEBCHERECQLTDP1
SCHEMBL2317073 0.81 KIT (0.78) KITBCHERECQLKDM4ERAB9A
SCHEMBL2309766 0.80 KIT (1.00) KITBCHERECQLKDM4ERAB9A
SCHEMBL12387249 0.79 ACHE (0.60) KITACHEBCHERECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989467-B2 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2011-08-02 US disclosed
EP-1663219-B1 USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS CENTRE NAT RECH SCIENT (FR) 2010-05-12 EP disclosed
US-20070054905-A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-03-08 US disclosed
EP-1663219-A2 USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-06-07 EP disclosed
WO-2005023255-A2 USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054905-A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process RBM17, BRCA1, SMN1; SMN2 KIT 2116/4885ACHE 239/4885BCHE 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.